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Background: Oral mucositis is one of the most frequent, irreversible and distressing complications faced 
by head and neck cancer (HNC) patients undergoing radiotherapy. Several studies have investigated the role 
of honey in the prevention and alleviation of radiation-induced oral mucositis in HNC patients, however, a 
definitive conclusion has not yet been generated. We performed this updated systematic review and meta-
analysis to determine whether honey can prevent and alleviate radiation-induced oral mucositis in HNC 
patients. 
Methods: We searched PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL) 
and China National Knowledge Infrastructure (CNKI) through October 2019. We searched and selected 
literature, extracted data and assessed risk of bias accordingly, and then conducted statistical analyses with 
RevMan software version 5.3. 
Results: Seven trials involving 412 patients were included in the final analysis. Meta-analyses showed that 
honey did not decrease the incidence of radiation-induced oral mucositis [(relative risk (RR), 0.69; 95% 
confidence interval (CI), 0.40–1.18; P=0.18]; however, relieved the severity of oral mucositis (RR, 0.22; 
95% CI, 0.13–0.38; P<0.001), maintained or increased weight (RR, 1.92; 95% CI, 1.33–2.77; P<0.001) 
and reduced the treatment interruption related to oral mucositis (RR, 0.13; 95% CI, 0.02–0.97; P=0.05). 
Qualitative analysis also revealed a decreased incidence of oral mucositis in the honey group. 
Conclusions: Based on limited evidence, honey may have a clinical benefit against radiation-induced oral 
mucositis in HNC patients. However, future trials with large-scale and rigorous methods are warranted to 
further establish the role of honey in the management of radiation-induced oral mucositis.
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Introduction
Head and neck cancers (HNC) are the sixth most common 
cancer around the world (1), with estimated new cases 
of 710,000 in 2018 (2). Radiotherapy (RT) alone or in 
combination with chemotherapy or surgery remains a 
cornerstone in treating HNC (3). Unfortunately, RT also 
damages epithelium and submucosal connective tissue 
and then causes inflammation (4). Cancer patients will 
experience oral mucositis when radiation destructed oral 
mucosal integrity (5). 
Oral mucositis has been emerging as the most frequent, 
inevitable and distressing complication faced by HNC 
patients treated with RT (6). Published studies revealed 
that almost of all HNC patients undergoing RT would 
experience oral mucositis (7). Evidence also suggested that 
about half of HNC patients experience grade 3 and above 
oral mucositis if exposure of the large mucosal surface to 
66–70 Gy radiation in 6–7 weeks with 1.8–2 Gy per fraction 
(8-10). Oral mucositis leads to pain, difficulty swallowing, 
nutritional issues, increased risk of infection and treatment 
interruption. It significantly impacts on patients' quality 
of life (QoL) (11). In addition, severe mucositis prolongs 
the hospital stay and increases medical expenditure (12). 
Thus, it is critical to develop effective methods to prevent 
and treat oral mucositis because the treatment interruption 
jeopardizes the cancer-destroying effect of RT and 
magnifies the chance of tumor cell repopulation (13). 
Numerous pharmacological and non-pharmacological 
interventions have been developed to treat radiation-
induced oral mucositis (14), such as oral zinc sulfate (15) 
and laser therapy (16). However, a definitive intervention 
regime has not yet been established (17,18). Therefore, 
it is essential to explore alternative agent. Honey is the 
by-product of flower nectar and the upper aero-digestive 
tract of the honeybee, which becomes concentrated by the 
dehydration process inside the beehive (5). As an ancient 
medicament, honey has been established effective in several 
fields, such as burn wounds, oral infections and surgical 
wound (19,20). To date, numerous clinical trials have been 
designed to explore the role of honey in preventing and 
treating radiation-induced oral mucositis in HNC patients. 
Severa l  sys temat ic  rev iews  and meta-ana lyses 
comprehensively evaluated the efficacy of honey in the 
management of radiation-induced oral mucositis (21-28). 
However, most of these reviews did not distinguish between 
RT and chemoradiotherapy. Out of these reviews, only one 
published in 2013 specifically investigate the role of honey 
for managing oral mucositis in HNC patients who were 
treated with RT alone (21). Regrettably the review included 
two ineligible trials in which patients were treated with 
combination regime of RT plus chemotherapy. Yarom et al. 
performed a systematic review to summarize the available 
evidence of natural agents in the prevention and treatment 
of oral mucositis in cancer patients, and concluded no 
guideline was possible (29). So, it remains unclear whether 
honey use can prevent and treat oral mucositis in HNC 
patients receiving RT. It is essential to investigate the efficacy 
of honey in the management of radiation-induced oral 
mucositis separately because the differences between RT 
and chemotherapy cannot be ignored (30). We consequently 
designed this updated systematic review and meta-analysis 
to accurately determine the role of honey in the prevention 
and treatment of radiation-induced oral mucositis in HNC 
patients.
Methods
We performed the current systematic review and meta-
analysis according to the criteria proposed by the Cochrane 
Collaboration (CC) (31). We reported all results following 
the framework issued in the Preferred Reporting Items 
for Systematic Reviews and Meta-Analysis (PRISMA) 
statement (32).
Selection criteria
We designed the selection criteria in line with the previous 
review (21), which was strongly associated with our topic: 
(I) adult HNC patients undergoing RT alone; (II) patients 
in the treatment group assigned to use honey and patients 
in the control group took control regime or received no 
treatment; (III) the incidence of severe oral mucositis (grade 
3 and 4) was the primary outcome, and the incidence of 
oral mucositis regardless of grade, incidence of weight 
maintenance, incidence of treatment interruption and 
honey-related adverse events were the secondary outcomes; 
and (IV) clinical trials including clinical controlled trials 
(CCTs) and randomized controlled trials (RCTs) were 
considered to meet our criteria. Conference abstracts with 
sufficient information were also considered to be eligible. 
Language of trials was limited to English and Chinese.
A trial will be excluded if at least one of following criteria 
was covered: (I) trial enrolled HNC patients who were 
also treated with chemotherapy in addition to RT, (II) trial 
provided insufficient information to enable a judgment, (III) 
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trial enrolled patients who had undergoing oral mucositis 
treatment previously, and (IV) poor methodology (assessed 
by XT).
Definition of outcomes
In the current study, the incidence of radiation-induced 
oral mucositis was defined as the value of a number of oral 
mucositis cases, irrespective of the grade, divided by the 
total number of HNC patients completing the whole study. 
The severity of oral mucositis was evaluated with a scoring 
system released by the Radiation Therapy Oncology Group 
(RTOG), World Health Organization (WHO) or the Oral 
Mucositis Assessment Scale (OMAS) (25). Grade 3 or 4 is 
considered intolerable or severe according to the established 
scales (23). The incidence of weight maintenance and the 
incidence of treatment interruption related to oral mucositis 
was defined as the value of a number of static or positive 
weight gain and study discontinuation divided by the total 
number of cancer patients completing the whole study 
respectively.
Identification of eligible literature 
Two investigators were assigned to independently 
search all citations in four databases including PubMed, 
EMBASE, Cochrane Central Register of Controlled 
Trials (CENTRAL) and China National Knowledge 
Infrastructure (CNKI) from its inception through October 
2019. We also hand-checked the reference lists of all 
eligible trials and topic-related reviews so that any potential 
trial can be covered. Search strategies were constructed 
by combining Medical Subject Headings (MeSH) and text 
words according to the unique requirements of individual 
database (33). The key terms used, including: honey, 
radiation, and oral mucositis. We documented all search 
strategies of English databases in the Supplementary File. 
We used Endnote X7.0 software to manage all citations.
Data extraction
Two investigators were assigned to independently select the 
eligible trials according to the selection criteria and extract 
data from each eligible trial with standard sheet. In this 
study, we extracted the information including first author, 
publication year, country of leading author, sample size, 
sex ratio, age of patients, details of intervention regimes, 
details of radiation dosages, and outcomes of interest. Any 
disagreement about inclusion and the extraction of the basic 
information and data were resolved by consulting a third 
author.
Assessment of risk of bias
Two investigators were assigned to independently evaluate 
the risk of bias from the following seven domains: 
randomization sequence generation, allocation concealment, 
blinding of participants and personnel, blinding of outcome 
assessors, incomplete outcome data, selective reporting, 
and other biases using the Cochrane risk of bias assessment 
tool (34). The overall quality of the methodology of an 
individual study was rated according to the matched 
level between the actual information and the evaluation 
criteria (35). Any disagreements between two investigators 
were addressed through consulting a third investigator.
Statistical analysis
In this review and meta-analysis, all outcomes were 
dichotomous data, and thus we used risk ratio (RR) with 
95% confidence interval (CI) to estimate it. We used a 
random-effects model to calculate all estimates because 
this model considering within and between studies’ 
heterogeneity simultaneously (36). We firstly adopted Q 
statistic to describe the heterogeneity qualitatively (37). We 
also used I2 statistic to quantitatively estimate the proportion 
of the overall variation (38). For a single outcome, we drew 
the funnel plot to qualitatively inspect the publication bias if 
the accumulated number of included studies was more than 
10 (39). We completed all statistical analyses with the 
RevMan 5.3 (Copenhagen, Denmark: The Nordic Cochrane 
Center, The Cochrane Collaboration, 2013).
Results
Identification and selection of eligible studies
We captured 144 items after initially searching for targeted 
electronic databases. We removed 66 duplicats after running 
‘Find Duplicates’ that is embedded in EndNote software. 
We classified 13 records into potential inclusion file after 
carefully reviewing the title and abstract of 78 items. We 
retrieved full-texts of 13 records in order to check the 
eligibility of each trial further. After excluding ineligible 
trials according to the following reasons: conference 
abstract (n=1), duplicates (n=1), and ineligible treatment 
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regime (n=5), we included 1 (40) and 6 trials (5,41-45) in the 
qualitative and quantitative analysis respectively. We drew 
Figure 1 to depict the process of identification and selection 
of eligible trials.
Details of characteristics of all eligible trials
We designed Table 1 to document details of characteristics 
of all eligible trials. All studies (5,40-45) were published 
between 2003 and 2017. The sample size of a single trial was 
ranging from 40 to 82, with a median sample size of 60. All 
trials used honey to prevent and treat radiation-induced oral 
mucositis. However, control regimes in eligible trials were 
different. Of 7 trials, 4 used normal saline (40,41,44,45), 
1 used lignocaine gel (43), 1 used water mouthwash (42), 
and 1 used standard protocol (5). Three trials used the 
Radiation Therapy Oncology Group (RTOG) grading 
system to evaluate the severity of oral mucositis (5,40,43), 
3 used the World Health Organization (WHO) grading 
system to assess the grade of oral mucositis (41,42,45), 
and 1 used the Oral Mucositis Assessing Scale (OMAS) 
to grade the severity of oral mucositis (44). Two trials 
reported an incidence of radiation-induced oral mucositis 
(5,41), 6 reported incidence of severe radiation-induced oral 
mucositis (5,41-45), and 2 reported weight maintenance and 
treatment interruption related to oral mucositis (5,41). All 
eligible trials reported that baseline information between 
honey and control groups was not statistically significant.
Assessment of risk of bias of single trial
We drew Figure 2 to show the details of the risk of 
bias of an eligible single trial. Of included 7 trials, 5 
reported the methods of generating random sequence 
in detail such as computer-generated random numbers 
and table of the random numbers (5,40-43). Only 1 trial 
conducted allocation concealment (43). Two trials stated 
the information of blinding investigator, participant and 
assessor (43,44). Furthermore, two trials did not adopt blind 
method (5,41). In summary, the overall level of quality of all 
eligible trials was regarded as moderate.
Meta-analysis of clinical outcomes
Incidence of oral mucositis
Of seven eligible trials, 2 involving 120 patients reported 
the incidence of oral mucositis after the patients were 
instructed to use honey (5,45). Meta-analysis revealed no 
Figure 1 Flow chart of identification and selection of eligible trials. Other sources refers to bibliography lists of eligible studies and topic-
related reviews.
Records identified through
database searching
(n=144)
Studies included in qualitative
synthesis
(n=1)
Additional records identified
through other sources
(n=1)
Studies included in quantitative
synthesis (meta-analysis)
(n=6)
Records after duplicates removed
(n=79)
Records screened
(n=14)
Full-text articles assessed for
eligibility
(n=7)
Records excluded
(n=65)
Full-text articles excluded, with
reasons (n=7)
Conference abstract (n=1)
Duplicates (n=1)
Chemo-radiotherapy (n=5)
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significant difference in the incidence of oral mucositis 
between the honey and control groups (two trials; RR, 0.69; 
95% CI, 0.40–1.18; P=0.18; I2 =81%; Figure 3A).
Incidence of severe oral mucositis
Among the seven eligible trials, six studies including 330 
patients reported the incidence of severe oral mucositis 
(5,41-45). Meta-analysis suggested that honey use was 
associated with decreased incidence of severe oral mucositis 
(six trials: RR, 0.22; 95% CI, 0.13–0.38; P <0.001, I2 =9%, 
Figure 3B).
However, one study (40) reported the incidence of 
severe oral mucositis lesions, which were inconsistent with 
results in other trials. So, it was not incorporated into meta-
analysis. However, we used descriptive analysis to clarify 
the findings. This trial found that the incidence of severe 
radiation-induced oral mucositis lesions in the honey 
group was significantly lower than that in control group (P 
value of Grade 3 mucositis: 0.016 and P value of Grade 4 
mucositis: 0.032).
Weight maintenance
Two trials involving 100 patients, out of seven eligible trials, 
reported weight maintenance (5,41). Meta-analysis revealed 
a higher proportion of static or positive weight gain in 
patients who were instructed to use honey compared to 
patients were assigned in control group (two trials; RR, 1.92; 
95% CI, 1.33–2.77; P<0.001, I2 =0%, Figure 3C). 
Oral mucositis induced treatment interruption 
Out of seven eligible trials, two reported the incidence of 
oral mucositis induced treatment interruption (5,41). The 
meta-analysis suggested a lower incidence of oral mucositis 
induced treatment interruption in honey group (two trials; 
RR, 0.13; 95% CI, 0.02–0.97; P=0.05, I2 =0%, Figure 3D). 
Honey related adverse events
For all eligible trials, no complications related to the 
administration of honey were reported. Moreover, no report 
of study discontinuation because of honey.
Publication bias
In the present systematic review and meta-analysis, the 
accumulated number of eligible trials for each outcome of 
interesting were all less than ten. We therefore did not draw 
a funnel plot to check potential publication bias.
Discussion
According to the latest data issued by the IARC, HNCs 
remain the critical threat to publics around the world (2). 
RT plays an important role in the comprehensive treatment 
of HNCs (44). Although RT can effectively destroy cancer 
cells, it also causes damage to healthy tissues located in the 
radiation portals due to the cytotoxic effect (44). As the 
most common acute complication of RT, oral mucositis 
will occur after the mucous membrane integrality was 
broken (46). Radiation-induced oral mucositis will cause 
a series of adverse consequences such as pain, discomfort, 
dysphagia, dehydration, micronutrient deficiency, weight 
loss (41). To effectively prevent and treat this condition, 
several intervention regimes have been developed (47). 
However, an effective, safe and convenient regime is still 
not established. It is, therefore, necessary to investigate the 
value of other alternative regimes for the prevention and 
treatment of radiation-induced oral mucositis in patients 
Figure 2 Risk of bias summary. Green, yellow and red solid circle 
represents low, unclear and high risk of bias respectively.
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with HNC. 
Honey has been used as a prophylactic or therapeutic 
agent since ancient times (48). Experimental studies 
suggested that honey has the potential of maintaining 
integrity of cellular epithelium tissue, preventing the inter-
cellular rupture and inhibiting bacterial growth because 
of its high viscosity, acidic PH, hydrogen peroxide, high 
osmolarity, and rich nutritional properties (43,49). According 
to the findings from several RCTs, honey can enhance 
healing of minor burns compared with conventional methods 
such as polyurethane dressings and silver sulfadiazine 
dressing (48-52). In this review, we first elucidate the efficacy 
and safety of honey to prevent and treat radiation-induced 
oral mucositis in HNC patients. Our meta-analysis suggested 
that honey could significantly decrease the incidence of 
severe radiation-induced oral mucositis (RR, 0.22; 95% 
Figure 3 Meta-analysis of clinical outcomes. (A) incidence of oral mucositis, (B) incidence of severe oral mucositis, (C) incidence of weight 
maintenance, and (D) incidence of treatment interruption. CI, confidence interval; M-H, Mantel Haenszel.
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CI, 0.13–0.38; P<0.001). Moreover, our qualitative analysis 
also suggested a decreased incidence of severe radiation-
induced oral mucositis in the honey group (P value of Grade 
3 mucositis: 0.016 and P value of Grade 4 mucositis: 0.032). 
Additionally, the meta-analysis also found that honey did 
significantly maintain the weight of patients with HNC 
(RR, 1.92; 95% CI, 1.33–2.77; P<0.001) and decrease the 
incidence of treatment interruption related to oral mucositis 
(RR, 0.13; 95% CI, 0.02–0.97; P=0.05). Several confounding 
factors such as baseline nutritional status were reported in 
included studies. So the result of weight maintenance must 
be cautiously interpreted.
To date, nine systematic reviews and meta-analyses have 
been conducted to explore the role of honey in preventing 
and treating radiation- or chemoradiation-induced oral 
mucositis in cancers. However, a conclusive finding for HNC 
patients has not yet been generated. Song and colleagues, in 
2012, performed a systematic review and meta-analysis to 
investigate the protective effects against radiation-induced 
oral mucositis in HNC, and demonstrated that honey use 
reduced the incidence of oral mucositis (25). This study 
enrolled three eligible trials, however one out of three trials 
recruited most patients receiving chemo-radiotherapy (53). 
Thus, five potential trials were missed (40-42,44,45). 
In 2013, a systematic review of five trials, performed by 
Charalambous et al. investigating the effectiveness of honey 
for the management of RT-induced oral mucositis in HNC 
patients, and found a clinical benefit of honey to radiation-
induced oral mucositis (21). Unfortunately, two trials 
involved patients who were prescribed to the combination 
treatment of RT and chemotherapy instead of RT alone 
(53,54), and quantitative analysis was also not performed. As 
a result, four eligible trials were not considered (40-42,45). 
In 2015, Cho et al. conducted a meta-analysis of nine eligible 
trials to explore the effects of honey on oral mucositis in 
HNC patients. However, only three trials of prescribing 
RT alone to patients were included. It is noted that this 
review performed subgroup analysis to separately inveterate 
the impact of honey on patients undergoing RT alone, 
and revealed that honey had a significantly higher effect in 
preventing moderate to severe mucositis (28). Unfortunately, 
this study enrolled an ineligible trial which was published 
in 2013 (41). In 2016, Co and colleagues performed a 
meta-analysis of five trials to quantitatively investigate the 
effect of honey on clinical outcomes among HNC patients 
receiving RT (22). However, among the five trials, only four 
prescribed RT. Furthermore, the review failed to capture 
three potentially eligible trials (22). In the same year of 
the review published, Xu et al. designed a meta-analysis to 
investigate the effects of honey on the management of radio/
chemotherapy-induced mucositis, and revealed that honey 
could effectively reduce the incidence of oral mucositis (26). 
Although the authors included seven trials in the final 
analysis, only three enrolled patients receiving RT alone, and 
regrettably, the other four trials were misleading (40-42,45). 
Furthermore, the study enrolled a trial investigating essential 
oils of manuka (Leptospermum scoparium) and kanuka 
(Kunzea ericoides) rather than manuka or kanuka honey (55). 
Yang et al. (2018) performed a network meta-analysis to 
explore the comparative efficacy of various kinds of honey 
for chemo/radiotherapy-induced oral mucositis (27). 
Although this study included twenty-one trials and 
designed several subgroup analyses according to the age 
of patients, cancer type and treatment regime, it is still 
difficult to determine the role of honey use in preventing 
and treating RT-induced oral mucositis in HNCs because 
of only eight trials focused on patients receiving RT or 
chemo/radiotherapy. Liu and colleagues (2019) performed 
a meta-analysis to investigate the impact of honey use 
on radiochemotherapy-induced mucositis. In this study, 
authors considered several cancer types such as HNCs, acute 
lymphoblastic leukemia (2 trials) and acute myeloid leukemia 
(1 trial). Moreover, it also enrolled 4 trials that participants 
were pediatric patients with HNC. Another review of 17 
trials performed by Münstedt and colleagues evaluated the 
role of honey in the management of side effects of RT- or 
radio/chemotherapy-induced oral mucositis (24). In this 
study, the authors used a qualitative approach to summarize 
all evidence. Unfortunately, however, trials prescribing 
RT alone were not analyzed separately. Moreover, the 
review failed to include one eligible trial published in the 
Chinese language. In 2013, Yarom et al. on behalf of the 
Mucositis Study Group of the Multinational Association of 
Supportive Care in Cancer and International Society of Oral 
Oncology (MASCC/ISOO) systematically documented the 
evidence for the use of natural agents for the management 
of oral mucositis and concluded that the available data 
were insufficient to reach a consensus (29). Moreover, this 
review considered an ineligible study that enrolled patients 
receiving chemo-radiotherapy (53). Compare to these 
reviews, the present study has two advantages. Firstly, seven 
eligible trials were analyzed, and this enables robust and 
reliable findings; secondly, our review only included trials 
that were specifically focusing on patients receiving RT 
alone. Thus, the risk of impairing the validity and reliability 
of pooled results of honey for the efficacy and safety of oral 
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mucositis was reduced.
In the present systematic review and meta-analysis, 
we captured seven eligible trials with an accumulated 
sample size of 412 patients to generate more robust pooled 
results. However, some limitations of our study must be 
acknowledged. Firstly, three instruments were used to grade 
the severity of radiation-induced oral mucositis across trials; 
this variation may impair the comparability of these results. 
A consistent instrument, therefore, should be adopted in 
future trials. Secondly, control regimes used in the included 
trials were different including normal saline, lignocaine 
gel, water and blank control. Inappropriate control regime 
may increase the risk of performance bias and thus decrease 
the reliability of findings. Therefore, we suggest using 
a uniform control regime in future trials such as normal 
saline. Thirdly, all analyzed trials focused on the clinical 
outcomes such as incidence of intolerable radiation-induced 
oral mucositis, however other outcomes from patients’ 
perspective such as quality of life were not investigated. 
Therefore, more outcomes should be designed in future 
trials. Fourthly, the sample size of individual eligible trial 
was insufficient, and thus future trials with large scale and 
rigorous methodology must be considered. Fifthly, our 
review did not address confounding variables for analyzing 
weight maintenance and treatment interruption related to 
oral mucositis due to insufficient data. So the pooled results 
for these outcomes should be cautiously interpreted. More 
importantly, future trials should report detailedly baseline 
variables. Sixthly, our review did not design subgroup 
analysis according to the RT machines because sufficient 
information cannot be extracted. We therefore suggest 
future trials to describe the details of RT. 
In conclusion, oral honey may have the potential of 
relieving the severity of radiation-induced oral mucositis, 
maintaining weight, and decreasing the incidence of 
treatment interruption related to oral mucositis in patients 
with HNC based on the limited evidence. Considering 
limitations in all included trials, we suggest designing future 
trials with large-scales and rigorous methods to further 
establish the role of oral honey for radiation-induced oral 
mucositis.
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Supplementary
Search strategies for English-language databases
Search strategy of PubMed
Search Query
#13
Search (((((“Neoplasms”[Mesh]) OR ((((((((((((((Cancer[Title/Abstract]) OR Neoplasia[Title/Abstract]) OR Neoplasias[Title/Abstract]) 
OR Neoplasm[Title/Abstract]) OR Neoplasms[Title/Abstract]) OR Tumors[Title/Abstract]) OR Tumor[Title/Abstract]) OR  
Cancers[Title/Abstract]) OR Malignancy[Title/Abstract]) OR Malignancies[Title/Abstract]) OR Malignant[Title/Abstract]) OR  
Malignant Neoplasm[Title/Abstract]) OR Benign Neoplasms[Title/Abstract]) OR Benign Neoplasm[Title/Abstract]))) AND  
((((“Radiation”[Mesh]) OR “Radiotherapy”[Mesh])) OR (((((((((((Radiation[Title/Abstract]) OR Radiotherapy[Title/Abstract]) OR  
Radiotherapies[Title/Abstract]) OR Radiation Theray[Title/Abstract]) OR Radiation Therapies[Title/Abstract]) OR Radiation  
Treatment[Title/Abstract]) OR Radiation Treatments[Title/Abstract]) OR Targeted Radiotherapies[Title/Abstract]) OR Targeted  
Radiotherapy[Title/Abstract]) OR Targeted Radiation Therapy[Title/Abstract]) OR Targeted Radiation Therapies[Title/Abstract]))) 
AND ((((“Mucositis”[Mesh]) OR “Stomatitis”[Mesh])) OR ((((((((Mucositis[Title/Abstract]) OR Mucositides[Title/Abstract]) OR  
Stomatitis[Title/Abstract]) OR Stomatitides[Title/Abstract]) OR Oral Mucositis[Title/Abstract]) OR Oral Mucositides[Title/Abstract]) 
OR Oromucositis[Title/Abstract]) OR Oromucositides[Title/Abstract]))) AND ((“Honey”[Mesh]) OR Honey[Title/Abstract])
#12
Search (“Neoplasms”[Mesh]) OR ((((((((((((((Cancer[Title/Abstract]) OR Neoplasia[Title/Abstract]) OR Neoplasias[Title/Abstract]) OR 
Neoplasm[Title/Abstract]) OR Neoplasms[Title/Abstract]) OR Tumors[Title/Abstract]) OR Tumor[Title/Abstract]) OR Cancers 
[Title/Abstract]) OR Malignancy[Title/Abstract]) OR Malignancies[Title/Abstract]) OR Malignant[Title/Abstract]) OR Malignant  
Neoplasm[Title/Abstract]) OR Benign Neoplasms[Title/Abstract]) OR Benign Neoplasm[Title/Abstract])
#11
Search (((((((((((((Cancer[Title/Abstract]) OR Neoplasia[Title/Abstract]) OR Neoplasias[Title/Abstract]) OR Neoplasm[Title/Abstract]) 
OR Neoplasms[Title/Abstract]) OR Tumors[Title/Abstract]) OR Tumor[Title/Abstract]) OR Cancers[Title/Abstract]) OR  
Malignancy[Title/Abstract]) OR Malignancies[Title/Abstract]) OR Malignant[Title/Abstract]) OR Malignant Neoplasm 
[Title/Abstract]) OR Benign Neoplasms[Title/Abstract]) OR Benign Neoplasm[Title/Abstract]
#10 Search “Neoplasms”[Mesh]
#9 Search (“Honey”[Mesh]) OR Honey[Title/Abstract]
#8 Search Honey[Title/Abstract]
#7 Search “Honey”[Mesh]
#6
Search (((“Radiation”[Mesh]) OR “Radiotherapy”[Mesh])) OR (((((((((((Radiation[Title/Abstract]) OR Radiotherapy[Title/Abstract]) 
OR Radiotherapies[Title/Abstract]) OR Radiation Theray[Title/Abstract]) OR Radiation Therapies[Title/Abstract]) OR Radiation 
Treatment[Title/Abstract]) OR Radiation Treatments[Title/Abstract]) OR Targeted Radiotherapies[Title/Abstract]) OR Targeted 
Radiotherapy[Title/Abstract]) OR Targeted Radiation Therapy[Title/Abstract]) OR Targeted Radiation Therapies[Title/Abstract])
#5
Search ((((((((((Radiation[Title/Abstract]) OR Radiotherapy[Title/Abstract]) OR Radiotherapies[Title/Abstract]) OR Radiation  
Theray[Title/Abstract]) OR Radiation Therapies[Title/Abstract]) OR Radiation Treatment[Title/Abstract]) OR Radiation  
Treatments[Title/Abstract]) OR Targeted Radiotherapies[Title/Abstract]) OR Targeted Radiotherapy[Title/Abstract]) OR Targeted 
Radiation Therapy[Title/Abstract]) OR Targeted Radiation Therapies[Title/Abstract]
#4 Search (“Radiation”[Mesh]) OR “Radiotherapy”[Mesh]
#3
Search (((“Mucositis”[Mesh]) OR “Stomatitis”[Mesh])) OR ((((((((Mucositis[Title/Abstract]) OR Mucositides[Title/Abstract]) OR 
Stomatitis[Title/Abstract]) OR Stomatitides[Title/Abstract]) OR Oral Mucositis[Title/Abstract]) OR Oral Mucositides[Title/Abstract]) 
OR Oromucositis[Title/Abstract]) OR Oromucositides[Title/Abstract])
#2
Search (((((((Mucositis[Title/Abstract]) OR Mucositides[Title/Abstract]) OR Stomatitis[Title/Abstract]) OR Stomatitides 
[Title/Abstract]) OR Oral Mucositis[Title/Abstract]) OR Oral Mucositides[Title/Abstract]) OR Oromucositis[Title/Abstract]) OR  
Oromucositides[Title/Abstract]
#1 Search (“Mucositis”[Mesh]) OR “Stomatitis”[Mesh]
Search strategy of CENTRAL
Search Name: Honey for Oral mucositis
Last Saved: 19/10/2019 01:07:41
Comment:
ID Search
#1 ("mucositis"):ti,ab,kw OR ("mucositides"):ti,ab,kw OR ("stomatitis"):ti,ab,kw OR ("stomatitides"):ti,ab,kw OR ("oral 
mucositis"):ti,ab,kw (Word variations have been searched)
#2 MeSH descriptor: [Stomatitis] explode all trees
#3 MeSH descriptor: [Mucositis] explode all trees
#4 #1 OR #2 OR #3
#5 ("radiation"):ti,ab,kw OR ("radiotherapy"):ti,ab,kw OR ("radiotherapies"):ti,ab,kw (Word variations have been 
searched)
#6 MeSH descriptor: [Radiation] explode all trees
#7 MeSH descriptor: [Radiotherapy] explode all trees
#8 #5 OR #6 OR #7
#9 ("cancer"):ti,ab,kw OR ("neoplasia"):ti,ab,kw OR ("neoplasm"):ti,ab,kw OR ("tumor"):ti,ab,kw OR 
("malignancy"):ti,ab,kw (Word variations have been searched)
#10 ("malignant"):ti,ab,kw OR ("benign neoplasm"):ti,ab,kw OR ("malignant neoplasm"):ti,ab,kw (Word variations have 
been searched)
#11 MeSH descriptor: [Neoplasms] explode all trees
#12 #9 OR #10 OR #11
#13 ("honey"):ti,ab,kw (Word variations have been searched)
#14 MeSH descriptor: [Honey] explode all trees
#15 #13 OR #14
#16 #4 AND #8 AND #12 AND #15
Search strategy of Embase
Embase
Session Results
No. Query Results 
#13. #3 AND #6 AND #9 AND #12 
#12. #10 OR #11 
#11. 'honey'/exp 
#10. honey:ti,ab,kw 
#9. #7 OR #8 
#8.	 'mucosa	inflammation'/exp	OR	'oral	mucositis'/exp	OR	'stomatitis'/exp
#7. mucositis:ti,ab,kw OR mucositides:ti,ab,kw OR stomatitis:ti,ab,kw OR stomatitides:ti,ab,kw OR 'oral 
mucositis':ti,ab,kw OR 'oral mucositides':ti,ab,kw OR oromucositis:ti,ab,kw OR oromucositides:ti,ab,kw
#6. #4 OR #5 
#5. 'radiation'/exp OR 'radiotherapy'/exp 
#4. radiation:ti,ab,kw OR radiotherap*:ti,ab,kw OR 'radiation therapy':ti,ab,kw OR 'radiation therapies':ti,ab,kw OR 
'radiation treatment':ti,ab,kw OR 'radiation treatments':ti,ab,kw OR 'targeted radiotherapies':ti,ab,kw OR 'targeted 
radiotherapy':ti,ab,kw OR 'targeted radiation therapy':ti,ab,kw OR 'targeted radiation therapies':ti,ab,kw
#3. #1 OR #2 
#2. 'malignant neoplasm'/exp OR 'neoplasm'/exp 
#1. cancer*:ti,ab,kw OR neoplasia*:ti,ab,kw OR neoplasm*:ti,ab,kw OR tumor*:ti,ab,kw OR malignanc*:ti,ab,kw 
OR malignant*:ti,ab,kw OR 'malignant neoplasm':ti,ab,kw OR 'malignant neoplasm*':ti,ab,kw OR 'benign 
neoplasms':ti,ab,kw OR 'benign neoplasm':ti,ab,kw
